LPU
BNR

Lansdowne Partners (UK)’s Burning Rock Biotech BNR Stock Holding History

Lansdowne Partners (UK)’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,259
Closed -$119K – 36
2023
Q3 		$119K Buy
+12,259
New +$191K 0.01% 35

Other funds holding BNR

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

Lansdowne Partners (UK)'s BNR Position: Q4 2023 in Review

Lansdowne Partners (UK) sold out of Burning Rock Biotech (BNR) in Q4 2023, closing a stake of 12,259 shares — an estimated $119K sold.

Lansdowne Partners (UK) first reported a position in BNR in Q3 2023 and held it in 1 quarter. The position peaked at $119K in Q3 2023. 19 funds tracked by Wall St. Rank hold BNR as of Q4 2023.

  • Lansdowne Partners (UK) reported no remaining Burning Rock Biotech position as of Q4 2023 after selling out during the quarter.
  • Lansdowne Partners (UK) sold 12,259 Burning Rock Biotech shares in Q4 2023, an estimated $119K.
  • Lansdowne Partners (UK) first reported a position in Burning Rock Biotech in Q3 2023 and held it in 1 quarter.
  • Lansdowne Partners (UK)'s Burning Rock Biotech position peaked at $119K in Q3 2023.
  • 19 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2023.

Based on Lansdowne Partners (UK)'s 13F filing for Q4 2023, filed 14 Feb 2024.